Scholarlink

Background <p>Oral corticosteroids (OCS) are widely used in the management of pediatric asthma exacerbations and recurrent wheezing. Despite their established efficacy, concerns about safety, optimal dosing, and appropriate clinical contexts persist.</p> Methods <p>This narrative review synthesizes evidence from studies published between 2000 and 2025, focusing on the efficacy, safety, and clinical applications of OCS in children. Pharmacological data were also included from earlier literature.</p> Results <p>Evidence indicates that OCS remain essential for managing moderate-to-severe asthma exacerbations in school-age children. In preschool wheezing, their benefit is inconsistent and appears limited to selected subgroups, such as children with virus-associated wheezing or established asthma. Short courses and lower doses provide comparable efficacy with improved tolerability. Among the available molecules, dexamethasone has emerged as a promising alternative due to better palatability and adherence, while deflazacort shows comparable efficacy but requires further validation.</p> Conclusions <p>The role of OCS in pediatric respiratory disease should be individualized, balancing efficacy and safety. Future studies should refine patient selection and evaluate alternative corticosteroid molecules to optimize therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

State of art of oral corticosteroids in children with acute asthma and wheezing

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月29日

查看全文
  • Carmen Mazzuca,
  • Rocco Luigi Valluzzi,
  • Andrea Ficari,
  • Lucia Lo Scalzo,
  • Sara Urbani,
  • Arianna Cafarotti,
  • Alessandro Fiocchi,
  • Vincenzo Fierro

摘要

Background

Oral corticosteroids (OCS) are widely used in the management of pediatric asthma exacerbations and recurrent wheezing. Despite their established efficacy, concerns about safety, optimal dosing, and appropriate clinical contexts persist.

Methods

This narrative review synthesizes evidence from studies published between 2000 and 2025, focusing on the efficacy, safety, and clinical applications of OCS in children. Pharmacological data were also included from earlier literature.

Results

Evidence indicates that OCS remain essential for managing moderate-to-severe asthma exacerbations in school-age children. In preschool wheezing, their benefit is inconsistent and appears limited to selected subgroups, such as children with virus-associated wheezing or established asthma. Short courses and lower doses provide comparable efficacy with improved tolerability. Among the available molecules, dexamethasone has emerged as a promising alternative due to better palatability and adherence, while deflazacort shows comparable efficacy but requires further validation.

Conclusions

The role of OCS in pediatric respiratory disease should be individualized, balancing efficacy and safety. Future studies should refine patient selection and evaluate alternative corticosteroid molecules to optimize therapeutic strategies.